- Global Pharma News & Resources

Immuno-oncology Development Trends and Opportunities

Immuno-oncology Development Trends and Opportunities

PR Newswire

NEW YORK, Dec. 6, 2018

NEW YORK, Dec. 6, 2018 /PRNewswire/ -- Immuno-oncology Development Trends and Opportunities


Read the full report:

"Immuno-oncology Development Trends and Opportunities", report provides an overview of current clinical development trends for Immuno-Oncology (IO) within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China), including a history of recent approvals, indications currently being explored for Immuno-Oncology (IO) agents of all modalities, targets being selected for Immuno-Oncology (IO) therapies, and combination strategies being investigated for approved Immuno-Oncology (IO) agents.

In addition, the report provides disease overviews, epidemiology, current recommended treatment regimens and Immuno-Oncology (IO) approvals, and Immuno-Oncology (IO) clinical trial trends for 17 indications identified on the basis of representing the largest commercial opportunities for Immuno-Oncology (IO) agents. Clinical trial trends analyze ongoing trials by sponsor type and modality, as well as ongoing combination trials for approved Immuno-Oncology (IO) therapies.

Immuno-Oncology (IO) is the treatment of cancer with therapies that stimulate or suppress the body's own immune system. Several distinct modalities of IO therapy exist, including bispecific T-cell engaging monoclonal antibodies, cellular immunotherapy and adoptive cellular therapy, cancer vaccines, checkpoint modulating monoclonal antibodies, and oncolytic viruses.

This report combines primary research from a cross-specialty panel of oncology experts with in-house analyst expertise to provide an assessment of the development landscape.

Components of the slide deck include primary and secondary research -
- Quotes from 13 US-, 5EU-, and Japan-based key opinion leaders
- Summary of IO product definitions and classifications
- Overview of development opportunities for IO agents across indications, including emerging indications and clinical targets, and novel combination strategies
- Outline of 17 key indications for IO agents, including current EU and US guideline recommendations, IO's current place in the treatment algorithm, and a review of ongoing clinical trials
- Call-outs of key information and details
- Insight from GlobalData's specialist oncology analysts.

Reasons to buy
- Develop business strategies by understanding the trends shaping and driving IO in the 8MM.
- Drive revenues by understanding the key trends, innovative combination strategies and indications likely to impact the IO market in the future.
- Design your development strategy through a review of potential novel targets or combinations across indications.
- Organize your sales and marketing efforts by understanding IO combination approaches across indications that present maximum opportunities for consolidations, investments, and strategic partnerships.
- Develop strategies by understanding expert perceptions of unmet needs in key indications in oncology, and the potential for IO agents to meet those needs.

Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare:
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:

SOURCE Reportlinker

Editor Details

Last Updated: 06-Dec-2018